Amyris Inc (NASDAQ: AMRS) is having an incredibly strong day in the market today, and for good reason. The company announced that Q1 sales broke records. As a result, an investor frenzy ensued, leading to gains in the value of the stock and prompting our partners at Trade Ideas to send the alert. At the moment (10:49), AMRS is trading at $0.62 per share after a gain of $0.04 per share (6.47%) thus far today.
AMRS Announces Record Q1 Sales
As mentioned above, Amyris is having an incredibly strong day in the market today after announcing that Q1 sales broke records. The record was broken for Biossance brand sales. Not only is the brand delivering high-growth, but it is also expected to drive much better than expected 2017 results. In fact, Biossance Squalane + Peptide Eye Gell is currently the $1 selling eye product at SEPHORA.com, and the product continues to gain top reviews from leading industry publications. In a statement, John Melo, President and CEO at AMRS, had the following to offer:
“We are excited by the growing contribution Biossance is making to our personal care business, and the robust growth we are experiencing in our nutrition business… We are off to a great start for the year driving growth across our business while pursuing strategic opportunities to improve our financial and competitive position as a leading company in our sector.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on AMRS. In particular, we’ll be watching the continued growth of eye care products. Also, last year, the company closed several significant contracts that will likely lead to more products and revenue throughout the year. We’ll continue to follow the story closely and bring the news to you as it breaks!
Want The News Faster?
Check out the CNA Finance News Desk to get the news before we have the time to write the full story!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Wikipedia]